Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

ABSTRACT: Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

SUBMITTER: Hanauer SB 

PROVIDER: S-EPMC1954967 | biostudies-literature | 2007 Sep

REPOSITORIES: biostudies-literature